米国市場銘柄情報

MOR モルフォシス

銘柄追加

17.915
+0.025+0.14%

取引中 05/06 13:36 ET

27.03億時価総額-5455直近PER

モルフォシスに関するコメント

ログインコメントを投稿

Trytosaveabit

02/07 03:00

WOW! Anyone else read this yet! Grrrrr! What’s true! Hehehe

$モルフォシス(MOR.US)$ MorphoSys Spokesperson Says "This Story Is Factually Wrong" In An Emailed Statement To Bloomberg News, In Response To STAT News' Adam Feuerstein Article Entitled, "Why Novartis Is Going To Walk Away From Its Acquisition"
Benzinga· 5 mins ago
Why Novartis is going to walk from its acquisition of MorphoSys (statnews.com)
Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not c...

Moomoo AI

02/06 17:32

Palantir's Q4 commercial business performance was 'bombastic, baller, incomprehensibly good', according to CEO Alex Karp. Coherent sees 'improving demand trends', expecting 'ongoing sequential improvement in revenue growth'. Chegg's Q1 guidance disappointed investors. NXP Semiconductors' Q4 results surpassed expectations. Novartis' acquisition of MorphoSys is viewed positively.

These Stocks Are Moving the Most Today: Palantir, BP, Eli Lilly, Coherent, Chegg, Spotify, and More -- Barrons.com

Trytosaveabit

02/06 00:34

Sry a bit late! Was out!

$モルフォシス(MOR.US)$ Novartis in Lead to Acquire Cancer-Drug Maker MorphoSys, Reuters Reports

Trytosaveabit

2023/12/11 10:24

Update

$モルフォシス(MOR.US)$ MorphoSys' Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
Pelabresib and ruxolitinib combination significantly reduced spleen size, with an SVR35 response rate nearly double that of placebo plus ruxolitinib Showed a strong positive trend in reducing symptom burden and a twofold increase in patients achieving both SVR35 and TSS50 versus placebo plus ruxolitinib Improved measures of anemia, including higher hemoglobin response rates, ...

Meltyy

2023/11/22 16:19

Why Is MorphoSys Stock Down 20% Today?

$モルフォシス(MOR.US)$ stock is falling hard on Tuesday after the company released data from a Phase 3 clinical trial of pelabresib.
The study evaluated pelabresib as a treatment for myelofibrosis in combination with ruxolitinib. It included patients treated with these two drugs as well as a placebo arm just treated with ruxolitinib.
The results from the clinical trial saw pelabresib meet its primary endpoint. There was also statistical significance observed ...

Trytosaveabit

2023/11/21 06:01

$モルフォシス(MOR.US)$ The German pharmaceutical company said Monday its Phase 3 trial of pelabresib in combination with ruxolitinib in myelofibrosis patients found a statistically significant and clinically meaningful improvement in the portion of patients with a 35% or greater reduction in spleen volume after 24 weeks.

Trytosaveabit

2023/11/21 05:42

News

$モルフォシス(MOR.US)$ MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

Options Newsman

2023/10/21 10:06

コラムStocks with Notable Option Volatility: MOR, REPL and SRPT.

Implied volatility is a measure of the market's expectation of the potential price movements of the stock in the future. Here are the stocks with the most notable implied volatility today.
$モルフォシス(MOR.US)$'s stock remained unchanged during the previous trading session. However, options volume was notable at 3.93K and the implied volatility percentile stood at an impressive 96.0%. This means that option traders are anticipating a signif...

まだコメントはありません

分析

アナリスト評価

データなし

目標株価

データなし

ホット

米国株

総合人気